Molecular Detection of Isoniazid Monoresistance Improves Tuberculosis Treatment: A Retrospective Cohort in France. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue The Journal of Infection Année : 2022

Molecular Detection of Isoniazid Monoresistance Improves Tuberculosis Treatment: A Retrospective Cohort in France.

(1) , (1, 2, 3, 4) , (5) , (3) , (1) , (4, 6, 1) , (7) , (8) , (9) , (10) , (11)
1
2
3
4
5
6
7
8
9
10
11

Résumé

OBJECTIVES: Isoniazid-monoresistant tuberculosis (HR-TB) requires early diagnosis and adapted treatment to achieve optimal outcomes. The primary aim of the study was to assess the impact of the implementation of rapid diagnostic tests on HR-TB treatment in France. METHODS: We designed a retrospective multicentre study including consecutive HR-TB patients diagnosed in 2016 and 2017. Implementation of a molecular assay detecting isoniazid resistance directly on a clinical sample was recorded. The association between early implementation of such assays and adequate treatment was assessed by a multivariable Cox proportional hazards model. RESULTS: Overall, 99 HR-TB patients were included from 20 University Hospitals. Among all smear-positive HR-TB patients, only 26% beneficiated from early molecular HR detection. This detection was independently associated with shorter time to adequate treatment (HR~=~2.0 [1.1-3.8], p~=~0.03). CONCLUSION: In our study, molecular detection of HR on an initial sample was independently associated with earlier treatment adaptation.
Fichier non déposé

Dates et versions

hal-03697160 , version 1 (16-06-2022)

Identifiants

Citer

Marwa Bachir, Lorenzo Guglielmetti, Simone Tunesi, Typhaine Billard-Pomares, Sheila Chiesi, et al.. Molecular Detection of Isoniazid Monoresistance Improves Tuberculosis Treatment: A Retrospective Cohort in France.. The Journal of Infection, 2022, 85 (1), pp.24--30. ⟨10.1016/j.jinf.2022.05.017⟩. ⟨hal-03697160⟩
16 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More